CELL INTELLIGENCE · 肿瘤细胞治疗研究

异基因 HSCT 复发后供者来源干细胞记忆 CAR-T 细胞的独特体内动力学

Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse.

Brexucabtagene autoleucel 用于 BTKi 初治复发/难治性套细胞淋巴瘤：ZUMA-2 队列 3 的主要分析

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.

面向新兴过继性细胞治疗的基于 PCR 的细胞动力学与生物分布分析展望

Perspectives on PCR-Based Cellular Kinetics and Biodistribution Analysis for Emerging Adoptive Cell Therapies.

放疗后长期缓解的孤立性口腔 CD30⁺/CD4⁺ CAR 阳性 T 细胞淋巴瘤

Isolated oral CD30(+)/CD4(+) CAR(+) T cell lymphoma in long-term remission after radiotherapy.

CD19 CAR-T 治疗大 B 细胞淋巴瘤的国际代谢预后指数优化与验证

Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma.

华氏巨球蛋白血症——最新综述：第 2 部分——聚焦治疗

Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy.

WM 无法治愈，但治疗可以提高生存率。WM/LPL 患者应在出现症状时开始治疗，IgM 水平不应决定 WM 治疗。当前指南建议采用各种初始个性化治疗，通常是化学免疫疗法 (CIT) 或 BTK 抑制剂 (BTKi)。

弥漫大 B 细胞淋巴瘤免疫治疗的未来

The future of immunotherapy for diffuse large B-cell lymphoma.

Axicabtagene ciloleucel 对比标准治疗用于二线大 B 细胞淋巴瘤：基于代谢肿瘤体积的结果

Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.

ZUMA-3 与历史试验中年龄 ≥26 岁复发/难治性 B 细胞急性淋巴细胞白血病患者的结局

Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials.

brexucabtagene autoleucel（ZUMA-2）与标准治疗（SCHOLAR-2）治疗复发/难治性套细胞淋巴瘤的间接治疗比较

Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.